Three-year European follow-up of endovenous radiofrequency-powered segmental thermal ablation of the great saphenous vein with or without treatment of calf varicosities  by Proebstle, Thomas M. et al.
Three-year European follow-up of endovenous
radiofrequency-powered segmental thermal
ablation of the great saphenous vein with or
without treatment of calf varicosities
Thomas M. Proebstle, MD, PhD,a Jens Alm, MD,b Oliver Göckeritz, MD,c Christian Wenzel, MD,c
Thomas Noppeney, MD,d Christian Lebard, MD,e Olivier Pichot, MD,f Carmine Sessa, MD,f and
Denis Creton, MD,g for the European Closure Fast Clinical Study Group, Mainz, Germany; Pecs,
Hungary; Hamburg, Leipzig, and Nürnberg, Germany; and Paris, Grenoble, and Nancy, France
Background: Radiofrequency segmental thermal ablation (RSTA) has become a commonly used technology for occlusion
of incompetent great saphenous veins (GSVs). Midterm results and data on clinical parameters are still lacking.
Methods: A prospective multicenteral trial monitored 295 RSTA-treated GSVs for 36 months. Clinical control visits
included flow and reflux analysis by duplex ultrasound imaging and assessment of clinical parameters according to the
CEAP classification and Venous Clinical Severity Score (VCSS).
Results: A total of 256 of 295 treated GSVs (86.4%) were available for 36 months of follow-up. At 36 months,
Kaplan-Meier survival analysis showed the probability of occlusion was 92.6% and the probability of no reflux was 95.7%,
and 96.9% of legs remained free of clinically relevant axial reflux. If complete occlusion was present at the 12-month
follow-up, the risk of developing new flow by 24 and 36 months of follow-up was 3.7% and 4.1%, respectively. Diameters
of the GSV measured 3 cm distal to the saphenofemoral junction reduced from 5.8  2.1 mm at screening to 2.2  1.1
mm at 36 months. The average VCSS score improved from 3.9  2.1 before treatment to 0.9  1.5 at 3 months (P <
.0001) and stayed at an average <1.0 during the complete 36 months of follow-up. Only 41.1% of patients were free of
pain before treatment; at 36 months, 251 (98.0%) reported no pain and 245 (95.7%) did not experience pain during the
24 months before. At 36 months, 189 of 255 legs (74.1%) showed an improvement in CEAP class compared with the
clinical assessment before treatment (P < .001). Stages C3 and C4 combined to 46% before treatment and dropped
constantly to a combined level of 8% at 36 months. However, the proportion of C2 legs that dropped from 52.3% before
treatment to <10% at 12 months showed a constant increase thereafter, reaching 33.3% at 36 months.
Conclusion: RSTA showed a high and durable success rate in vein ablation in conjunction with sustained clinical efficacy.
(J Vasc Surg 2011;54:146-52.)
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pShortly after its introduction, radiofrequency segmen-
tal thermal ablation (RSTA) became a technique used
worldwide for heat-induced obliteration of incompetent
great saphenous veins (GSVs). From the beginning, RSTA
achieved immediate GSV ablation rates of 99% in addi-
tion to a very moderate side effect profile and a remarkably
short average time interval for return to normal activity of
2 days.1,2 These findings have been corroborated re-
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146ently, describing occlusion rates of 98% to 100% at 6
onths of follow-up, further demonstrating that a vein
iameter 12 mm is not related to a decreased ablation
ate.3 In addition, a prospective randomized trial proved
hat the side effect profile of RSTA compared favorably
ith endovenous laser ablation using a 980-nm diode laser
nd typical blunt-tipped bare fibers.4
Because of the widespread use of RSTA, midterm re-
ults of the first clinical trial of RSTA, including the dura-
ility of once achieved GSV occlusions and the postinter-
entional course of clinical signs and scores, are of special
nterest. This report presents the 3-year update of the
uropean RSTA Study Group with follow-up data retrieval
rom up to 86.4% of treated patients.
ATIENTS AND METHODS
Study design. Within a prospective, nonrandomized,
ulticenter cohort study, results at 36 months were ob-
ained on safety data and clinical outcomes of RSTA of the
SV in otherwise unselected consecutive patients with
linically relevant chronic venous disease and GSV incom-
etence. Control visits, including duplex ultrasound
DUS) examination, were scheduled at 3 days and at 3, 6,
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Volume 54, Number 1 Proebstle et al 14712, 24, and 36 months after the study treatment. Previous
reports have described enrollment criteria, the study device,
the treatment procedure and its evaluation protocol with
patient follow-up, and also some feasibility data as well as
early safety and clinical outcome data of parts of this co-
hort.1,2 Study treatments were performed at eight clinical
sites in Germany and France after approval by local author-
ities and local ethical review boards according to the Dec-
laration of Helsinki and its later extensions.
Patient follow-up. Each follow-up visit consisted of a
clinical examination, the completion of a questionnaire,
and DUS examination of the treated leg in horizontal and
reverse Trendelenburg position. Supine position for DUS
examinations was preferred rather than standing to allow
comparison with diameters obtained intraoperatively.
The primary study end points were occlusion of and
lack of reflux in the treated vein. Vein occlusion was defined
as absence of any blood flow along the entire length of the
treated vein length determined by DUS imaging beginning
from 3 cm distal to the saphenofemoral junction (SFJ) and
continued from there. The 3-cm limit was selected because
the occlusion status of the GSV proximal to this limit
frequently had to be regarded nonspecific due to the vari-
able entry-site of several tributaries. On the other hand, a
precise measurement with a typical 4-cm length linear
ultrasound probe is still possible. Secondary end points
included the evaluation of side effects, adverse events,
clinical outcomes, and patient recovery after the treatment.
Patient symptoms and signs were recorded using the
CEAP clinical classification5 and the Venous Clinical Sever-
ity Score (VCSS).6 The side effects and complications asso-
ciated with the procedure were recorded and analyzed.
Postprocedural pain and tenderness, the latter represented
the discomfort level in response to touch or palpation, were
evaluated using an analog scale, with the minimum of 0
representing no pain and a maximum of 10 representing
worst possible pain. The analog scale was used in a nonvi-
sual fashion after explaining it to the patient.
Statistical methods. Baseline characteristics, includ-
ing demographics, medical history, or venous symptoms
were summarized using descriptive statistics. End point
analysis was performed at the 2-year follow-up or longitu-
dinally along distinct follow-up intervals if required. Mea-
surable parameters were expressed as mean  standard
deviation and proportions were expressed as percentage
with a 95% confidence interval. Data were analyzed on a
per-patient or a per-leg basis as appropriate for presentation
of clinical data. Patients with bilateral treatment were
treated as one for data analyzed on a per-subject basis. For
data analyzed on a per-leg basis, the two legs were treated
separately. If appropriate, for matched-pairs analysis only,
those patients and legs were evaluated who completed the
3-year follow-up.
Kaplan-Meier analysis was used to describe recurrences
of flow and reflux within treated veins. To protect across
inferences and to preserve size of , the type 1 error rate,
the Tukey-Kramer honestly significant difference test was
used to make multiple comparisons of means over time. montingency table analysis using likelihood ratio 2 statis-
ics were used to test the hypothesis that the response rates
ere the same in each sample category. Continuity cor-
ection was applied, and exact P values were computed
hen cell sparseness rendered the analysis suspect. All
nalysis was performed using SAS 9.2 software (SAS
nstitute Inc, Cary, NC).
ESULTS
A total of 225 patients and 295 legs were treated from
pril 2006 to March 2007 at eight study centers in Ger-
any and France. Patients with incompetent GSVs who
et inclusion and exclusion criteria were offered treatment
ithin this study. At the 3-year follow-up, 194 patients
ith 256 treated legs from seven centers were available,
epresenting a proportion of 86.2% and 86.8% of the orig-
nal study treatments, respectively. Thirty-one patients
ere not able to attend the 3-year follow-up, mainly be-
ause they moved to remote locations or because they
eclined further follow-up visits for personal reasons. Of
94 patients with follow-up at 3 years, 35.1% were treated
t the center with the highest recruitment. Only two cen-
ers contributed 5% of the treated patients.
Patient characteristics. Patients were an average age
f 47.1  12.1 years (range, 18-74 years). Women com-
rised 74.5% of treated individuals. The proportion of
omen was not69% in any study center. The mean body
ass index of the 225 patients was 25.3  4.6 kg/m2
range, 16.2-43.6 kg/m). Patient comorbidities were
oderate: 72 significant medical conditions among 49 of
he 214 patients (22.9%) were reported. Medical condi-
ions with a frequency of5% were arterial hypertension in
5 (17.8%) and thyroid disease in 19 (8.4%). Bilateral
reatments were performed in 66 of 214 patients (30.8%).
mong the 256 treated legs monitored for 36 months,
istribution was 127 right legs and 129 left legs, which was
lmost equal. The average treated length of the GSV from
he SFJ to the site of vein access at the distal point of reflux
as 36.8  10.5 cm. All RSTA interventions were per-
ormed under tumescent local anesthesia (TLA) with an
verage of 331 107 mL of TLA administered per treated
SV, corresponding to an average of 9.4 3.5 mL of TLA
er cm of treated vein length.
Of the 256 legs available at the 3-year follow-up, 30
11.7%) had undergone venous interventions previous to
tudy treatment, however, not affecting the GSV. These
ncluded 3 vein strippings, 1 patient each with ligation,
ndovenous laser and phlebectomy, radiofrequency abla-
ion, and radiofrequency ablation with concomitant sclero-
herapy; 7 phlebectomies, 15 sclerotherapies, and 1 un-
pecified. Concomitantly with the study treatment,
hlebectomy was performed in 147 of 256 legs (57.4%)
nd foam sclerotherapy of tributaries in 31 legs (12.1%). An
ncompetent accessory anterior saphenous vein in one leg
as treated with segmental thermal ablation immediately
fter study treatment. During the study follow-up of 36
onths, 11 of 256 legs (4.3%) received additional treat-
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July 2011148 Proebstle et alments for persisting varicose tributaries, comprising phle-
bectomy in 1 and sclerotherapy in 10.
DUS examination of proximal vein diameter.
Immediately after segmental thermal ablation, vein occlu-
sion with absence of spontaneous and augmented flow was
demonstrated by US examination in all but one leg, which
showed delayed occlusion. Furthermore, vein wall thicken-
ing was evident immediately after treatment in 100% of the
GSVs. Pretreatment vein diameters measured in supine
position at 3 cm distal to the SFJ showed an average
diameter of 5.8  2.1 mm (range, 2.0-14.0 mm). Fig 1
displays the average vein diameters 3 cm inferior to the SFJ
and the time course of corresponding US measurements
during follow-up.
A pronounced shrinkage of the average diameter was
visible already at 1 week after the procedure to 4.5  1.7
mmwith a further reduction to 2.9 1.1 mm at 6 months,
resembling 78% and 49% of the pretreatment diameter,
respectively. Tukey-Kramer pair-wise analysis revealed sta-
tistically significant reductions (P  .05) in vein diameter
when comparing baseline values with all follow-up values
and when comparing diameters at 1 week and 3 months
with diameters at 6, 12, 24, and 36 months.
DUS examination of nonoccluded stump lengths of
the GSV. At the week 1 postprocedural follow-up, the
mean nonoccluded stump lengths at the SFJ of 250 GSVs
was 1.0  0.7 cm. No extension of the thrombus into the
common femoral vein was observed
Interestingly, the average nonoccluded stump lengths
of the treated GSV did not change much during the 36-
month follow-up. Corresponding values at 3, 6, 12, 24,
and 36 months were 1.2 0.7, 1.2 0.7, 1.1 0.7, 1.1 
0.7, and 1.2  0.7, respectively. Tukey-Kramer pair-wise
analysis revealed a relevant difference only between the
1-week and 3-month follow-up (P  .05), indicating that
increase of the nonoccluded stump lengths is not a natural
Fig 1. Diameters of 254 great saphenous veins (GSV) before
study treatment and its later fibrotic stages during follow-up as
measured 3 cm below the saphenofemoral junction. Numbers of
evaluable GSVs decreased to 112 at 36 months. Data are given as
average  standard error (green) and standard deviation (light
blue) as well as median (horizontal line) with 25% and 75% quan-
tiles (red box).process more than 3 months after the procedure. aFlow and reflux analysis. Blood flow and reflux were
ssessed by DUS examination along the treated vein from
he SFJ toward the distal point of study treatment. Recur-
ence of any blood flowmore distal than 3 cm from the SFJ,
ecurrence of any reflux, and recurrence of any axial reflux
n the treated leg originating from the SFJ were described
nd plotted according to the Kaplan-Meier method.
At 3 days after study treatment, one vein exhibited flow
ith augmentation and showed reflux along the entire
reated segment despite a narrowed lumen. This vein
as occluded at the 3-month follow-up and at all later
ollow-up dates. Therefore, this GSV was judged to have
elayed occlusion rather than reopening and was not in-
luded in the Kaplan-Meier analysis.
Recurrence of blood flow, reflux, and axial reflux.
y DUS examination, blood flow in any part of the treated
ein from 3 cm below the SFJ or more distally was observed
uring the 3-year follow-up in 21 GSVs. In reverse, no
lood flow within the treated GSV was observed in 99.7%,
8.6%, 96.3%, 94.5%, and 92.6% at 3, 6, 12, 24, and 36
onths. Standard error of the confounding Kaplan-Meier
nalysis (Fig 2, A) was5% at all times. If a leg reached the
2-month follow-up visit without detection of flow, the
hance to develop new flow during the consecutive 12
onths was 3.7%. If a leg reached the 24-month follow-up
isit without detection of flow, the chance to develop new
ow during the consecutive 12 months was 4.1%.
Reflux of 500-ms duration in any part of the treated
SV was observed by DUS examination during the 3-year
ollow-up in 12 GSVs. No reflux within the treated GSV
as observed in 99.7%, 99.3%, 99.0%, 97.2%, and 95.7% at
, 6, 12, 24, and 36 months, respectively (Fig 2, B).
tandard error was 1% at all times. If occlusion of the
reated GSV was observed at the 12-month follow-up, the
isk that new reflux would develop during 24 months of
ollow-up was 2.9%. If occlusion of the treated GSV was
bserved at 24 months, the risk of developing new reflux
uring 24 months of follow-up was 3.3%.
Axial reflux as defined recently,7 originating at the SFJ
nd conducted within the initially occluded GSV or by
ifferent parallel pathways down to the calf region, was
bserved during the 3-year follow-up in only five GSVs. As
eported in more detail in Table I,7 only two cases resulted
rom full recanalization of the RSTA-treated GSV, one at 6
onths and another after 36 months. In two legs the
ccessory anterior saphenous vein was involved as the route
f axial reflux, and in one instance carrying the reflux to
he distal thigh and entering the GSV at a point where no
tudy treatment was applied before due to a lack of incom-
etency at the time of study treatment. In the second leg
ith involvement of the accessory anterior saphenous vein,
he axial reflux was conducted through the GSV stump for
3 cm, then transferred to the proximal competent acces-
ory anterior saphenous vein. In the last leg, after a 6-cm
ecanalization, reflux was conducted down to the calf
hrough a ventral thigh tributary.
Clinical response to study treatment: CEAP. We
re well aware that the CEAP classification originally was
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however, the clinical part of CEAP was used for the restag-
ing of patients in yearly intervals and showed quite inter-
esting results.
The pretreatment maximum CEAP clinical class distri-
bution is summarized in Table II, showing 85.5% of legs
had a pretreatment CEAP class of C3, with C2 alone in
52.3%. In general, all 256 legs that were available at the
36-month follow-up were in CEAP classes C1 to C4 before
study treatment, except one leg in stage C6. However,
because clinical stage C6 is not fully reversible, contingency
analysis, as displayed in Fig 3, A, was limited to clinical
stages C0 to C4. Of these 255 legs assessed at 36 months,
189 (74.1%) showed an improvement in CEAP class if
compared with the clinical assessment before the study
treatment (P  .001). No change of CEAP class was
observed in 64 legs (25.1%), whereas CEAP class worsened
in only 2 legs (1%).
Remarkably, the proportion of legs in clinical stages of
Fig 2. A, Time-to-flow analysis shows any flow within the treated
vein, according to Kaplan-Meier methods. Numbers in the lower
line indicate legs at risk at a given follow-up time. B, Time-to-
reflux analysis, indicating any reflux within the treated vein, regard-
less if clinically relevant or not, is shown according to the method
of Kaplan andMeier. Numbers in the lower line indicate legs at risk
at a given follow-up time. Standard errors were 0.1 at all times.C2, C3, or C4 dropped from 99% to 20% during the first vear of follow-up and increased slightly to 30% at 2 years
nd to 41% at 3 years. However, the more severe clinical
tages C3 and C4 with 46% of legs before treatment showed
n ongoing improvement during follow-up reaching a pro-
ortion of finally 7% at 2 years and 8% at 3 years. Fig 3, B
isplays the most relevant CEAP stages C2 to C4 more
learly. It seems noticeable that the proportion of legs in
linical stage C2, after a drop from 52.3% before treatment
o10% immediately thereafter was increasing again slowly
oward the 2-year follow-up to a value of 20% and to
3.3% at 3 years. The proportion of legs in clinical stage C4,
owever, showed an ongoing constant drop from 14.1%
efore study treatment to almost 3% at the 2-year follow-up
nd 4% at the 3-year follow-up.
Clinical response to study treatment: VCSS. At
aseline, the average VCSS of 256 legs monitored for 36
onths was 3.9  2.1. The minimum VCSS observed at
tudy entry was 1, representing the sole presence of varicose
able I. Limbs with axial reflux7 from the
aphenofemoral junction of the calf region developing
fter successful ablation of the great saphenous vein
GSV) by study treatment
imb
First
observation Pattern of axial reflux during follow-up
6 months Full recanalization of RSTA-treated GSV
with reflux to midthigh, reflux to calf
region via anterolateral thigh tributary
down to calf level
24 months GSV recanalization with reflux along the
proximal 6 cm, then reflux via tributary
down to knee level, there re-entering the
GSV with continued reflux
24 months Axial reflux carried via incompetent
accessory anterior vein entering the GSV
slightly proximal knee level, GSV
incompetent distal from there.
Originally RSTA-treated part of the
GSV remained closed without flow
36 months Full recanalization of GSV with reflux
down to calf level
36 months Axial reflux through 2.7 cm stump of GSV
via neovascularization to accessory
anterior saphenous vein and down to
calf area
able II. Pretreatment CEAP class distribution of 280
imbs before study treatment
CEAP Class No. (%)
C0 0 (0.0)
C1 3 (1.1)
C2 143 (51.1)
C3 91 (32.5)
C4 41 (14.6)
C5 1 (0.4)
C6 1 (0.4)eins or venous edema with ankle swelling in the evening.
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of whom was a man classified C6 according to CEAP. This
patient presented with anmedial ankle ulceration of2-cm
diameter until the 3-month follow-up but showed no more
ulceration from 6 months of follow-up on.
The time course of VCSS along follow-up is displayed
in Fig 4. Interestingly, the drop of VCSS after study treat-
ment, but even more between 1 week and 3 months, was
maintained throughout the entire follow-up period. The
average VCSS score improved to 3.5 1.1 at 1 week and to
0.9 1.5 at the 3-month follow-up. Average VCSS stayed
0.7 up to 24 months but increased slightly to 0.9 at 36
months. However, the average reduction in VCSS scores
from screening and at 1 week to 3, 6, 12, 24, and 36
months were statistically significant at the .05 level, as
Fig 3. A, Mosaic plot of CEAP stages C0 to C4 during fo
B, Time course of the distribution of CEAP stages C2, Crevealed by Tukey-Kramer analysis. NInterestingly, before treatment, only 41.1% of patients were
ree of pain in the treated leg, at 36 months, 251 legs (98.0%)
ere reported free of pain, and 245 (95.7%) did not experience
ain in the treated leg during the 24months before.
Side effects. Side effects in generally were mild and oc-
urredwith a low frequency, as listed inTable III. Remarkably at
6 months, only 1 of 256 legs showed hyperpigmentation over
he course of the treatedGSV, and only 1 patient complained of
ersisting paresthesia in an area attributable to the saphenous
erve. No more side effects were detected at 3 months of fol-
ow-uporafterwardandgenerallyoccurredwitha lowfrequency.
ISCUSSION
Segmental thermal ablation has already been proven to
e a highly efficient and fast procedure for GSV ablation.1
-up from baseline until 36 months after study treatment.
d C4 after study treatment.llowow, 3-year follow-up showed that the high ablation rates
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also transfer into durable clinical benefits in VCSS and
clinical CEAP stage. In only 4.3% of treated GSVs was new
reflux detected by DUS imaging, and only 2.0% of treated
legs revealed new axial reflux with 86.4% of treated legs
examined at the 3-year follow-up.
The occlusion rate seems to be much better than the
one described for the preceding method with Closure
PLUS (VNUS Technologies).8 However, RSTA seemed to
preserve the favorable side effect profile despite delivering
linear energy densities9 of 120 J/cm during the first
treatment cycle and 70 J/cm thereafter. These energy
doses compare with current recommendations for en-
dovenous laser treatment of the GSV but elicited fewer side
effects in a prospective randomizedmulticenter trial against
980-nm laser treatment using bare fibers.4 In particular,
pain, tenderness, and ecchymosis were less frequent in the
segmental thermal ablation group during the first 2 weeks
after the procedure. These findings were corroborated by a
recent observational study comparing segmental thermal
ablation with 980-nm laser ablation.10 A paresthesia fre-
quency of 0.4% in our study compares favorably with
1470-nm endovenous laser ablation showing a paresthesia
Fig 4. Time course of the Venous Clinical Severity Score (VCSS)
during follow-up in 256 legs monitored for 36 months. Data are
given as average  standard error (green) and standard deviation
(light blue) as well as median (horizontal line) with 25% and 75%
quantiles (red box).
Table III. Frequency of side effects during follow-up
after segmental thermal ablation of initially 280 legs and
256 legs after 36 months
Follow-up interval
1
week
3
months
12
months
24
months
36
months
Ecchymosis, % 5.8 . . . . . . . . . . . .
Paresthesia, % 3.4 2.0 0.4 0.4 0.4
Pigmentation, % 2.4 1.4 1.0 1.1 0.4
Erythema, % 2.0 . . . . . . . . . . . .
Hematoma, % 1.4 . . . . . . . . . . . .
Phlebitis, % 1.0 . . . . . . . . . . . .
DVT/PE, % 0.0 . . . . . . . . . . . .
DVT, Deep vein thrombosis; PE, pulmonary embolism.rate of 7.6% at 12 months after treatment.11 tHeat-induced shrinkage of the GSV diameter, a surro-
ate marker for the delivery of a sufficient dose of thermal
nergy during endovenous ablation, 3 cm below the SFJ
howed a value of 78% at 1 week after segmental thermal
blation. A representative report on typical endovenous
aser ablation described shrinkage of 66% after 6 weeks.12
part from shrinkage, we focused on the nonoccluded
tump length of the GSV after segmental thermal ablation
erving as a natural sinus to collect venous blood from the
rea and also preventing thrombus extension during the
nitial phase after endothermal GSV ablation. In our study,
he nonoccluded stump length was at an average that was
onstant during the complete follow-up time of 36
onths, varying only slightly from 10 to 12 mm, suggest-
ng that an increasing stump length during follow-up is not
normal phenomenon, but instead may indicate proximal
ecanalization.
Even if the focus of today is on reduction of treatment-
elated side effects and reduction of periprocedural impair-
ent of patients’ quality of life, one still has to remember
hat the primary treatment goal is ablation of pathologic
efluxes in incompetent saphenous veins. Side effect reduc-
ion by delivery of lower energy doses seems easy; however,
oncomitant reduction of ablation rates may be a logic
onsequence, as in a recent report on 1500-nm laser abla-
ion with a delivered endovenous energy of only 53.4 J/cm
nd an occlusion rate that dropped to 93.3% by 6months of
ollow-up.13 Segmental thermal ablation actually provides
igh ablation rates (Fig 2) in conjunction with a very
oderate side effect profile. Such high ablation rates can
ven be achieved by RSTA with vein diameters 12 mm.3
n our study, only 5 of 256 legs (2.0%) presented with
ecurrent axial reflux.
Outcome measurement in treatment of venous disor-
ers cannot only rely on DUS evaluation of ablated saphe-
ous veins, even though it is a necessary condition for the
mprovement of the patient’s clinical condition. At the time
hen this study was designed, scores on instruments for
easurement of quality of life, such as the Medical Out-
omes Study Short Form 36 Health Survey14 and the
hronic Venous Insufficiency Quality of Life Question-
aire (CIVIQ),15 appeared not as mandatory as they are
oday and were not included in the protocol of this study.
Instead, clinical classification according to CEAP5 and
he VCSS6 were used to re-evaluate patients at any given
ollow-up interval, even though neither instrument was
esigned for measurement of treatment-related outcomes
n early clinical stages of venous disease. Before treatment,
CSS averaged about 5 (range 2-12), indicating moderate
enous disease in our patients. However, statistics were able
o show improvement of the VCSS to baseline 3 months
fter study treatment and, furthermore, that our patients
aintained this level throughout the 36-month follow-up
Fig 4).
CEAP is a detailed descriptive tool for classification of
enous disease but originally was not designed for measure-
ent of treatment success during follow-up. Interestingly,
he prevalence of skin changes (C4) in our study dropped
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(C3) disappeared almost instantly after study treatment and
did not recur during 36 months of follow-up in a relevant
proportion of patients. Varicose veins (C2) were not com-
pletely eliminated, because treatment of thigh-level tribu-
taries was not allowed by the study protocol. However,
after achieving a reduction of C2 to 10% to 15% during the
first year of follow-up, an increase to 30% was noticeable
at the 3-year follow-up, suggesting a risk of around 10% per
year to develop new C2-varicosities in a treated leg. This
may reflect the natural course of the disease; however, the
numbers reported in a case-control study over 5 years were
only 17% during the entire study period.16 In our study,
however, it remains unclear if this higher number of newC2
varicosities could be related to untreated thigh varicosities,
as requested by the study protocol, to avoid overlap in
treatment-related symptoms to the study procedure.
CONCLUSIONS
The 3-year follow-up after segmental thermal ablation
proves endured maintenance of an initially achieved abla-
tion rate of 100%, with only 2.0% of axial reflux during the
study follow-up of 36 months. This successful ablation is
achieved with a very moderate side effect profile and is
further connected to an improvement in CEAP class grad-
ing and VCSS. This highly effective treatment should be
compared with other modalities for treatment of incompe-
tent GSVs in prospective randomized trials.
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